Home > Boards > US OTC > Biotechs > Ampio Pharmaceuticals, Inc (AMPE)

Soon as we get the results from the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
TJG Member Profile
Member Level 
Followed By 562
Posts 27,242
Boards Moderated 3
Alias Born 06/20/07
160x600 placeholder
Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled PR Newswire (US) - 1/14/2021 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:59:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:58:29 PM
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients PR Newswire (US) - 1/4/2021 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/29/2020 4:18:32 PM
Ampio Receives feedback from the FDA on Ampio's Proposed Modifications to the special protocol assessment for Ampion treatmen... PR Newswire (US) - 12/29/2020 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:41:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:39:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:37:51 PM
Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion PR Newswire (US) - 12/17/2020 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2020 4:02:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2020 2:25:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2020 2:24:03 PM
Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug,... PR Newswire (US) - 12/10/2020 9:15:00 AM
Ampio Pharmaceuticals, Inc. to Host its Annual Meeting on December 12, 2020 PR Newswire (US) - 12/8/2020 9:15:00 AM
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress PR Newswire (US) - 12/2/2020 9:15:00 AM
Ampio Updates Regulatory and Clinical Trial Events PR Newswire (US) - 11/25/2020 9:15:00 AM
Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress PR Newswire (US) - 11/17/2020 9:15:00 AM
Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress PR Newswire (US) - 11/10/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 4:02:00 PM
Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results PR Newswire (US) - 11/5/2020 3:45:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/3/2020 9:32:51 AM
Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th PR Newswire (US) - 11/2/2020 9:15:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/30/2020 11:21:24 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/30/2020 11:13:06 AM
TJG Member Level  Thursday, 10/22/20 03:26:52 PM
Re: mining101 post# 859
Post # of 1131 
Soon as we get the results from the granted IND that the FDA gave us after the tests below were admitted this will go way up

The FDA requested comprehensive tests on the safety of nebulized Ampion at various doses. The results of these tests have been reviewed by independent toxicologists who found no evidence of toxicity in preclinical trials, even at extreme doses, and this extensive data has been submitted to the FDA.Aug 19, 2020

https://ampiopharma.com/news/ampio-provides-update-on-covid-19-clinical-trial-activities/#:~:text=The%20FDA%20requested%20comprehensive%20tests,been%20submitted%20to%20the%20FDA.

FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress
Date: September 21, 2020 | READ MORE >

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences